Last reviewed · How we verify

BCG-Japan

Bandim Health Project · FDA-approved active Biologic Quality 5/100

BCG-Japan is a Biologic drug developed by Bandim Health Project. It is currently FDA-approved. Also known as: Tokyo strain 172.

At a glance

Generic nameBCG-Japan
Also known asTokyo strain 172
SponsorBandim Health Project
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about BCG-Japan

What is BCG-Japan?

BCG-Japan is a Biologic drug developed by Bandim Health Project.

Who makes BCG-Japan?

BCG-Japan is developed and marketed by Bandim Health Project (see full Bandim Health Project pipeline at /company/bandim-health-project).

Is BCG-Japan also known as anything else?

BCG-Japan is also known as Tokyo strain 172.

What development phase is BCG-Japan in?

BCG-Japan is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing